Refine by
Pharmaceutical Bio Articles & Analysis
37 news found
This special offer is valid through December 4, 2024, at 23:59 EST.Our monodispersed PEGs are highly versatile and indispensable in various pharmaceutical and biotechnological applications. These precision-engineered compounds are widely used in PEGylation, a process that enhances the pharmacokinetics and stability of therapeutic molecules. ...
Changsha, China – Hunan Huateng Pharmaceutical Co., Ltd. is proud to provide high-quality monodispersed polyethylene glycols (PEGs) tailored for the evolving needs of antibody-drug conjugates (ADCs). ...
The company is renowned for providing comprehensive support to the bio-pharmaceutical industry, leveraging its expertise in PEG derivatives to enhance drug delivery systems and therapeutic performance. ...
Mohammed AlQuraishi’s laboratory, both in June of this year,” said Brian Weitzner, Ph.D. Outpace Bio’s Associate Director of Computational and Structural Biology and a co-founder of OpenFold. ...
Forbion invests in life sciences companies that are active in the (bio-) pharmaceutical space. Forbion manages well over EUR 2 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. ...
The selected companies from seven European countries are A4Cell, AbolerIS Pharma, Abscint, ANeuroTech, Aptus, Bloomlife, Clouds of Care, E-scopics, FluoSphera, Iomed, Lattice Medical, mimiX biotherapeutics, Neomatrix, Neuropath, Predilife, Pulsify Medical, Radiomics, Regen Lab, Smart immune, Transactiva, Vidac Pharma Ltd., Leucid Bio, miDiagnostics, MRM Health & Yoni ...
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announces that the company will be present at the upcoming BIO International Convention to be held in San Diego, CA June 13-16, 2022. François Ravenelle, PhD, Chief Executive Officer of Inversago; Glenn D. Crater, MD, Chief Medical Officer; and, ...
The Korea Health Industry Development Institute (KHIDI) announced on the 31st that it held the 'China Pharmaceutical Bio Investment Briefing (IR)' on the 20th, where domestic pharmaceutical companies introduced their technologies to Chinese investors. ...
Guy Chamberland, Chief Executive Officer and Chief Regulatory Officer of Tetra Bio-Pharma. About PPP004 PPP004 is a topical preparation containing either a standardized amount of CBD or a defined ratio of THC and CBD. The base product is a proprietary pharmaceutical-grade formulation composed of Active Pharmaceutical Ingredients (APIs) that ...
Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announced that François Ravenelle, PhD, Chief Executive Officer and Glenn D. Crater, MD, FCCP, Chief Medical Officer, will take part to the Presenting Company Class of 2022 at Bio€quity Europe. Details are as follows: MAY 16-18, 2022 ...
Panag Pharma Inc (Panag), a subsidiary of Tetra Bio-Pharma, will collect royalties on sales on products produced with the technology True North has licensed from Panag. ...
Health Canada approved the amendment of the phase I study to assess the effect of low and moderate doses of inhaled CBD in healthy cannabinoid users. The collaboration with the CRCHUM will allow Tetra to obtain phase I clinical data on inhaled CBD. OTTAWA, ON, March 8, 2022 /CNW/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in ...
Supply of Avicanna's Active Pharmaceutical Ingredients (APIs) for Tetra's pharmaceutical pipeline. The phyto-cannabinoid APIs would be sourced from Avicanna's low cost and sustainable operations in Colombia. Co-development and support for Avicanna's pharmaceutical pipeline for Health Canada and FDA level clinical development and registration. ...
Milan, January 27, 2022 – InnovHeart s.r.l., a developer of novel Transcatheter Mitral Valve Replacement (TMVR) systems for the treatment of mitral valve disease, announces the closing of its Series C financing with granting an exclusive licensing agreement to Grand Pharmaceutical Group Limited, (Grand Pharma) for its proprietary Saturn device in Greater China. ...
GLK-302 is the second investigational drug candidate utilizing Glaukos’ iLution platform’s patented cream-based drug formulations that are applied to the outer surface of the eyelid for dropless transdermal delivery of pharmaceutically active compounds for the treatment of eye disorders. GLK-302’s active pharmaceutical ingredient is pilocarpine. ...
GLK-301 is the first investigational drug candidate utilizing Glaukos’ iLution platform’s patented cream-based drug formulations that are applied to the outer surface of the eyelid for dropless transdermal delivery of pharmaceutically active compounds for the treatment of eye disorders. GLK-301’s active pharmaceutical ingredient is pilocarpine. ...
” About Glaukos Glaukos (www.glaukos.com) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. ...
Wainwright BioConnect 2022 Conference and participating in BIO Partnering at JPM. All events are virtual and scheduled concurrently with the J.P. ...
OTTAWA, ON, Dec. 21, 2021 /CNW Telbec/ - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development, is pleased to announce the closing of its marketed public offering (the "Offering") of 13,064,000 units of the Company (the "Units"), at a price of $0.163 per Unit for aggregate gross proceeds of $2.1 ...
Topic: Makya: AI-driven de novo drug design and multi-parametric optimisation Recording Duration: 56:50 Webinar Start Time: Dec 7, 2021, 10 - 11 AM CET & 5 - 6 PM CET Access to the Recorded ...
ByIktos